期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
mRNA-based modalities for infectious disease management 被引量:1
1
作者 Mengjie Zhang Abid Hussain +3 位作者 Haiyin Yang Jinchao Zhang Xing-Jie Liang Yuanyu Huang 《Nano Research》 SCIE EI CSCD 2023年第1期672-691,共20页
The novel coronavirus disease 2019(COVID-19)is still rampant all over the world,causing incalculable losses to the world.Major pharmaceutical organizations around the globe are focusing on vaccine research and drug de... The novel coronavirus disease 2019(COVID-19)is still rampant all over the world,causing incalculable losses to the world.Major pharmaceutical organizations around the globe are focusing on vaccine research and drug development to prevent further damage caused by the pandemic.The messenger RNA(mRNA)technology has got ample of attention after the success of the two very effective mRNA vaccines during the recent pandemic of COVID-19.mRNA vaccine has been promoted to the core stage of pharmaceutical industry,and the rapid development of mRNA technology has exceeded expectations.Beyond COVID-19,the mRNA vaccine has been tested for various infectious diseases and undergoing clinical trials.Due to the ability of constant mutation,the viral infections demand abrupt responses and immediate production,and therefore mRNA-based technology offers best answers to sudden outbreaks.The need for mRNA-based vaccine became more obvious due to the recent emergence of new Omicron variant.In this review,we summarized the unique properties of mRNA-based vaccines for infectious diseases,delivery technologies,discussed current challenges,and highlighted the prospects of this promising technology in the future.We also discussed various clinical studies as well preclinical studies conducted on mRNA therapeutics for diverse infectious diseases. 展开更多
关键词 messenger rna(mrna)vaccine lipid-nanoparticle infectious disease drug delivery coronavirus disease 2019(COVID-19) virus
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部